- Allergy Therapeutics has completed patient enrolment for its phase IIb dose-finding study, G204, in the US.

GrassMATAMPL is an ultra-short course subcutaneous allergen specific immunotherapy administered prior to the grass pollen season.

Total patient enrolment for the Phase IIb study was 250 patients and headline data is expected at the end of the first half of 2016, paving the way for the US Phase III study.

At 9:42am: [LON:AGY] Allergy Therapeutics PLC share price was +0.63p at 26.63p

Story provided by